THE EXPRESSIONS AND SIGNIFICANCES OF p15,p16 AND VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) IN GASTRIC CARCINOMA

To investigate the relationships between the expressions of p15,p16 and vascular endothelial growth factor (VEGF) and gastric carcinoma(GC). Methods: Using Immunohistochemical staining to examine the expressions of p15, p16 and VEGF In archival wax-embedded specimens of 80 GC and 20 gastric benign disease (GBD). Results: The positive expression rate (PER) of p15 was significantly lower in GC than in GBD (43.75% VS. 69.23%, P<0.05). No relationship was found between PER of p15 and clinicopathologic factors. PER of p16 was 20% in GC, 55% in GBD (P<0.01). PER of p16 wasn't significantly different in gross types, histological types, with or without distant metastasis and pTNM stages. PER of p16 was 71.43% in invasive mucosa or submucosa group, 17.24% in invasive muscle group and 13.64% in invasive serosa group (P<0.01); 12.96% in GC with lymph nodes metastasis, 34.62% in GC without lymph node metastasis (P<0.05). PER of VEGF in GC was 75.00%, in GBD 7.69% (P<0.001), in ul-cerative type of GC and infiltrating

To investigate the relationships between the expressions of p15,p16 and vascular endothelial growth factor (VEGF) and gastric carcinoma(GC). Methods: Using Immunohistochemical staining to examine the expressions of p15, p16 and VEGF In archival wax-embedded specimens of 80 GC and 20 gastric benign disease (GBD). Results: The positive expression rate (PER) of p15 was significantly lower in GC than in GBD (43.75% VS. 69.23%, P<0.05). No relationship was found between PER of p15 and clinicopathologic factors. PER of p16 was 20% in GC, 55% in GBD (P<0.01). PER of p16 wasn't significantly different in gross types, histological types, with or without distant metastasis and pTNM stages. PER of p16 was 71.43% in invasive mucosa or submucosa group, 17.24% in invasive muscle group and 13.64% in invasive serosa group (P<0.01); 12.96% in GC with lymph nodes metastasis, 34.62% in GC without lymph node metastasis (P<0.05). PER of VEGF in GC was 75.00%, in GBD 7.69% (P<0.001), in ul-cerative type of GC and infiltrating type of GC were 81.97% and 40.00%, respectively (P <0. 05), in GC of invasive serosa was 95. 45%, in GC of Invasive muscle 51. 72% (P<0.001), in GC of invasive mucosa or submucosa 42.86% (P<0.001). PER of VEGF in GC with lymph node metastasis was 82. 8%, without lymph node metastasis 54. 6% (P<0.05), in GC accompanied with distant metastasis was 100%, in GC without distant metastasis 71.1% (P<0.05). PER of VEGF in pTNM Ⅰ and Ⅱ was 53.13%, in Ⅲ and Ⅳ 89.56% (P<0.001). The expression of p15 correlated significantly with that of VEGF (P <0.001) and with that of pl6 (P<0.01) in GC. Conclusion: p15 expression down-regulation has relationship with GC, but no relationship with the progress. p16 expression downregulation and VEGF expression up-regulation show significant relationships with clinicopathologic factors. There are significant relations between p15 and p16 negative expressions and between p15 expression down-regulation and VEGF expression up-regulation.